27.00
Janux Therapeutics Inc (JANX) 最新ニュース
Janux Therapeutics stock hits 52-week low at $28.92 By Investing.com - Investing.com South Africa
Janux Therapeutics stock hits 52-week low at $28.92 - Investing.com India
Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? - Yahoo Finance
Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March - MSN
We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow - Yahoo Finance
12 Best Up and Coming Stocks to Buy According to Wall Street Analysts - Insider Monkey
First Week of JANX November 21st Options Trading - Nasdaq
RA Capital Management, L.P. Increases Stake in Janux Therapeutics Inc - GuruFocus.com
Insiders Are Spending Big: 15 Stocks Leading in March - Insider Monkey
Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey
10 Worst High-Risk High-Reward Growth Stocks To Buy - Insider Monkey
Commit To Buy Janux Therapeutics At $25, Earn 30% Annualized Using Options - Nasdaq
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR
Janux Therapeutics (NASDAQ:JANX) Shares Gap Up Following Insider Buying Activity - Defense World
Insiders Are Loading Up on These 4 Biotech Stocks Now - 24/7 Wall St.
(JANX) Proactive Strategies - news.stocktradersdaily.com
JANX stock touches 52-week low at $29.62 amid market shifts By Investing.com - Investing.com South Africa
JANX stock touches 52-week low at $29.62 amid market shifts - Investing.com India
Sunday Insider Moves: Top Buys and Sells from Friday’s Disclosures By Investing.com - Investing.com Australia
Sunday Insider Moves: Top Buys and Sells from Friday’s Disclosures - Investing.com India
Ra Capital Management, L.P. Purchases 341,742 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - Defense World
Ra Capital Management, L.P. Purchases 110,206 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - Defense World
Major Investment Alert: Janux Therapeutics Stock Sees Massive Buy-In! - TipRanks
Proficio Capital Partners LLC Invests $1.35 Million in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Ra capital management buys $25.3 million in Janux therapeutics stock By Investing.com - Investing.com Australia
Ra capital management buys $25.3 million in Janux therapeutics stock - Investing.com
HC Wainwright Has Pessimistic Outlook of JANX Q1 Earnings - Defense World
Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Friday - Defense World
Janux Therapeutics chief business officer sells shares for $107,174 By Investing.com - Investing.com South Africa
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Janux Therapeutics chief business officer sells shares for $107,174 - Investing.com India
Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently - Insider Monkey
JANUX THERAPEUTICS Earnings Preview: Recent $JANX Insider Trading, Hedge Fund Activity, and More - Nasdaq
10 Stocks With At Least $30 Million In Insider Spending Recently - Insider Monkey
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Rhumbline Advisers - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Holdings Lifted by New York State Common Retirement Fund - Defense World
Janux Therapeutics (NASDAQ:JANX) Given “Buy” Rating at HC Wainwright - Defense World
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week Low on Analyst Downgrade - Defense World
Promising Developments and Strong Financial Position Support Buy Rating for Janux Therapeutics - TipRanks
Janux Therapeutics’ (JANX) Outperform Rating Reiterated at Wedbush - Defense World
Positive Outlook for Janux Therapeutics Inc. Driven by Unique Therapeutic Potential and Strategic Advantages - TipRanks
Janux Therapeutics price target lowered to $41 from $62 at Scotiabank - Yahoo Finance
Janux Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks
Janux Therapeutics (NASDAQ:JANX) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
Analyst Recommends ‘Buy’ for Janux Therapeutics Inc. Amid Share Price Decline and Promising Clinical Outlook - TipRanks
大文字化:
|
ボリューム (24 時間):